Cardiology
Partner With Us
Advertisement
Conexiant chevron_right Cardiology chevron_right BMI Influences Antiplatelet Therapy Outcomes in Patients Who Experienced AMI
From the Journals

BMI Influences Antiplatelet Therapy Outcomes in Patients Who Experienced AMI

Deescalation from ticagrelor to clopidogrel after PCI showed significantly better outcomes in AMI patients with BMI < 28, primarily through reduced bleeding risk

Conexiant
article Full Article subject Summary summarize Notecard
A post hoc analysis of the TALOS-AMI trial suggests that de-escalation strategies for antiplatelet therapy in patients with acute myocardial infarction following percutaneous coronary intervention may vary by body mass index (BMI). The study found that patients with a BMI < 28 experienced significantly reduced adverse events with de-escalation, mainly due to fewer bleeding complications, while those with a BMI ≥ 28 did not show a statistically significant benefit. The findings highlight the influence of BMI on clinical outcomes and caution against a definitive interpretation of the BMI threshold of 28. However, the study's limitations, including its post hoc nature and limited generalizability, should be considered.

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.